Board Resignation
-
Poxel Announces Corporate Governance Changes Following Reorganization Filing
Poxel SA, facing insolvency proceedings, has overhauled its board and leadership. The entire existing board resigned, replaced by Sophie Jacq Lapointe (Chairman), Nicolas Trouche (CEO), Amit Kohli, and Alexandre Bragadir. Trouche succeeds Thomas Kuhn as CEO. Lapointe brings pharmaceutical commercialization expertise, while Trouche specializes in restructuring. Kohli has expertise in diabetes therapies and Bragadir in healthcare financing. Poxel’s focus remains on MASH and rare metabolic disorder treatments, including PXL065 and PXL770, and its diabetes drug TWYMEEG®. The new leadership aims to navigate restructuring and secure funding.
